Democratic political strategist James Carville blasted a CNN anchor's comparison between Democrats and January 6 rioters, calling it "way outside the strike zoneDemocratic political strategist James Carville blasted a CNN anchor's comparison between Democrats and January 6 rioters, calling it "way outside the strike zone

James Carville shuts down CNN host's 'way outside the strikezone' remark

2026/05/31 05:22
2 min read
For feedback or concerns regarding this content, please contact us at [email protected]

Democratic political strategist James Carville blasted a CNN anchor's comparison between Democrats and January 6 rioters, calling it "way outside the strike zone."

During an appearance with CNN's Michael Smerconish, Carville started talking about the hard-nose tactics Democrats should adopt. He defended Rock legend Bruce Springsteen's Trump trashing at a recent concert and voters who support embattled Maine Senate candidate Graham Platner.

James Carville shuts down CNN host's 'way outside the strikezone' remark

Carville also proudly declared, "I have Trump Derangement Syndrome, and I'm trying to get worse," adding he thinks Springsteen has it too.

However, Smerconish was trying to make the point that "Democrats have a blind eye. They're turning a blind eye to their own failings, and I look at Platner with his Nazi tattoo for nearly twenty years as Exhibit A," he told Carville.

"When the intensity and desire is only to beat Donald Trump, it's not in the party's best interest because they lose their judgment," Smerconish argued. "It's the same mindset that explains people who breached the Capitol on January 6. They were similarly warped in their thinking."

Carville fired back, "I completely disagree," and said "assaulting police officers" is nothing like "voting for a flawed person" like Platner.

"Breaking into the Capitol is a felony," Carville argued. "If you're calling balls and strikes, I'm gonna call this way outside the strike zone."

In fact, he doubled down and said that Democrats "need to do more" and be outspoken like Springsteen.

"I might have Trump Derangement Syndrome, but I am not a criminal," Carville said. "We are being led by a person who, if not a traitor himself, is doing exactly everything that a traitor would do if they got that job."

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin is poised for a reversal if ETF demand returns or a ceasefire occurs, potentially crushing short sellers in a massive price squeeze.
Share
Coin Telegraph2026/04/04 19:58
Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Inertia is the invisible tax on modern industrial throughput. Every millisecond a robotic arm spends decelerating, or waiting for high-frequency vibrations to settle
Share
Techbullion2026/04/02 18:25

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage